MedTrace Logo

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

NCT05814107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-11-28

No results posted yet for this study

Summary

This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).

Conditions

Interventions

DRUG

CT-996

Capsule of CT-996

DRUG

Placebo

Capsule of placebo matching CT-996.

Sponsors & Collaborators

  • Carmot Therapeutics, Inc.

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Carmot Australia First Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Carmot Therapeutics, Inc., a Member of the Roche Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-09
Primary Completion
2025-11-07
Completion
2025-11-07

Countries

  • Australia
  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05814107 on ClinicalTrials.gov